Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Background: The PARP inhibitor olaparib has been shown to have clinical efficacy in patients with a germline BRCA mutation and ovarian or breast cancer. However, the high treatment cost associated with this drug limits its viability as a clinical treatment option. This work aims to evaluate the cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Zheng, Huanrui, Huang, Yanlei, Zheng, Bin, Cai, Hongfu, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096350/
https://www.ncbi.nlm.nih.gov/pubmed/33959007
http://dx.doi.org/10.3389/fphar.2021.632818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096350/
https://www.ncbi.nlm.nih.gov/pubmed/33959007
http://dx.doi.org/10.3389/fphar.2021.632818

Ejemplares similares